Quotes 5-day view Delayed Nasdaq
01/20/2021
01/21/2021
01/22/2021
01/25/2021
01/26/2021
Date
44.65(c)
44.62(c)
47.56(c)
49.59(c)
48.99 Last
490 882
439 514
761 178
787 827
961 699 Volume
+1.43% -0.07% +6.59% +4.27% -1.21% Change
Sales 2020
217 M - -
Net income 2020
-158 M - -
Net Debt 2020
-
-
-
P/E ratio 2020
-29,4x
Yield 2020
-
Sales 2021
477 M - -
Net income 2021
-66,9 M - -
Net Debt 2021
-
-
-
P/E ratio 2021
-53,2x
Yield 2021
-
Capitalization
4 513 M 4 513 M -
Capi. / Sales 2020
20,8x
Capi. / Sales 2021
9,47x
Nbr of Employees
531
Free-Float
91,9%
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small...
Notations Surperformance© of FibroGen, Inc.
Trading Rating : Investor Rating :
All news about FIBROGEN, INC.
News in other languages on FIBROGEN, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends FIBROGEN, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
10
Average target price
61,88 $
Last Close Price
49,59 $
Spread / Highest target
83,5%
Spread / Average Target
24,8%
Spread / Lowest Target
-11,3%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
